Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission.


Journal

The lancet. Gastroenterology & hepatology
ISSN: 2468-1253
Titre abrégé: Lancet Gastroenterol Hepatol
Pays: Netherlands
ID NLM: 101690683

Informations de publication

Date de publication:
02 2019
Historique:
received: 24 07 2017
revised: 10 08 2018
accepted: 13 08 2018
entrez: 17 1 2019
pubmed: 17 1 2019
medline: 2 6 2020
Statut: ppublish

Résumé

Viral hepatitis is a major public health threat and a leading cause of death worldwide. Annual mortality from viral hepatitis is similar to that of other major infectious diseases such as HIV and tuberculosis. Highly effective prevention measures and treatments have made the global elimination of viral hepatitis a realistic goal, endorsed by all WHO member states. Ambitious targets call for a global reduction in hepatitis-related mortality of 65% and a 90% reduction in new infections by 2030. This Commission draws together a wide range of expertise to appraise the current global situation and to identify priorities globally, regionally, and nationally needed to accelerate progress. We identify 20 heavily burdened countries that account for over 75% of the global burden of viral hepatitis. Key recommendations include a greater focus on national progress towards elimination with support given, if necessary, through innovative financing measures to ensure elimination programmes are fully funded by 2020. In addition to further measures to improve access to vaccination and treatment, greater attention needs to be paid to access to affordable, high-quality diagnostics if testing is to reach the levels needed to achieve elimination goals. Simplified, decentralised models of care removing requirements for specialised prescribing will be required to reach those in need, together with sustained efforts to tackle stigma and discrimination. We identify key examples of the progress that has already been made in many countries throughout the world, demonstrating that sustained and coordinated efforts can be successful in achieving the WHO elimination goals.

Identifiants

pubmed: 30647010
pii: S2468-1253(18)30270-X
doi: 10.1016/S2468-1253(18)30270-X
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

135-184

Subventions

Organisme : Department of Health
ID : RP-2016-07-012
Pays : United Kingdom
Organisme : Department of Health
ID : EME/14/02/17
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L002086/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R011117/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P025064/1
Pays : United Kingdom

Investigateurs

Ayman Abdo (A)
Rakesh Aggarwal (R)
Alessio Aghemo (A)
Bandar Al-Judaibi (B)
Mamun Al Mahtab (M)
Arshad Altaf (A)
Zyaad Ameen (Z)
Tarik Asselah (T)
Oidov Baatarkkhuu (O)
Ella Barber (E)
Eleanor Barnes (E)
Pascale Boulet (P)
Louise Burrows (L)
Maia Butsashvili (M)
Erica Chan (E)
Chelsea Chow (C)
Ben Cowie (B)
Chris Cunningham (C)
Alexandre de Araujo (A)
Graciela Diap (G)
Greg Dore (G)
Joseph Doyle (J)
Manal Elsayed (M)
Emmanuel Fajardo (E)
Ed Gane (E)
Aneley Getahun (A)
David Goldberg (D)
Tiffany Got (T)
Matthew Hickman (M)
Andrew Hill (A)
Sharon Hutchinson (S)
Chris Jones (C)
Saleem Kamili (S)
Amreen Khan (A)
Alice Lee (A)
Tin Yan Lee (TY)
Jioiji Malani (J)
Tammy Meyers Morris (TM)
Shevanthi Nayagam (S)
Richard Njouom (R)
Ponsiano Ocama (P)
Alisa Pedrana (A)
Rosanna Peeling (R)
Amulya Reddy (A)
Jilian Sacks (J)
Shiv Sarin (S)
Yusuke Shimakawa (Y)
Marcela Silva (M)
Pavlo Skala (P)
Simon Taylor-Robinson (S)
Alex Thompson (A)
Mark Thursz (M)
Alfred Tonganibeia (A)
Jack Wallace (J)
James Ward (J)
Fernando Wolff (F)
Peter Vickerman (P)
Johnny Yau (J)

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : ErratumIn

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Graham S Cooke (GS)

Division of Infectious Diseases, Imperial College London, London, UK. Electronic address: g.cooke@imperial.ac.uk.

Isabelle Andrieux-Meyer (I)

Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland.

Tanya L Applegate (TL)

The Kirby Institute, UNSW Sydney, NSW, Sydney, Australia.

Rifat Atun (R)

Harvard T H Chan School of Public Health, Harvard University, Boston, MA, USA; Harvard Medical School, Harvard University, Boston, MA, USA.

Jessica R Burry (JR)

MSF Access Campaign, Geneva, Switzerland.

Hugo Cheinquer (H)

Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.

Geoff Dusheiko (G)

Liver Unit, Kings College Hospital, London, UK.

Jordan J Feld (JJ)

Toronto Center for Liver Disease, Toronto General Hospital, Toronto, Canada.

Charles Gore (C)

Medicines Patent Pool, Geneva, Switzerland.

Max G Griswold (MG)

Institute of Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Saeed Hamid (S)

Aga Khan University, Karachi, Pakistan.

Margaret E Hellard (ME)

Burnet Institute, Melbourne, VIC, Australia.

JinLin Hou (J)

Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Guangzhou, China.

Jess Howell (J)

Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, VIC, Australia.

Jidong Jia (J)

Liver Research Center, Beijing Friendship Hospital, Beijing, China.

Natalia Kravchenko (N)

Alliance for Public Health, Kyiv, Ukraine.

Jeffrey V Lazarus (JV)

Health Systems Research Group, Barcelona Institute for Global Health (ISGlobal), Hospital Clinic, University of Barcelona, Barcelona, Spain.

Maud Lemoine (M)

Division of Surgery and Cancer, Imperial College London, London, UK.

Olufunmilayo A Lesi (OA)

College of Medicine, University of Lagos, Lagos, Nigeria.

Liudmyla Maistat (L)

Medicines Patent Pool, Geneva, Switzerland.

Brian J McMahon (BJ)

Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AL, USA.

Homie Razavi (H)

Center for Disease Analysis Foundation, Lafayette, CO, USA.

Teri Roberts (T)

MSF Access Campaign, Geneva, Switzerland.

Bryony Simmons (B)

Division of Infectious Diseases, Imperial College London, London, UK.

Mark W Sonderup (MW)

Division of Hepatology, Department of Medicine, University of Cape Town, South Africa.

C Wendy Spearman (CW)

Division of Hepatology, Department of Medicine, University of Cape Town, South Africa.

Bridie E Taylor (BE)

World Hepatitis Alliance, London, UK.

David L Thomas (DL)

Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Imam Waked (I)

National Liver Institute, Menoufiya University, Egypt.

John W Ward (JW)

Program for Viral Hepatitis Elimination, Task Force for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Stefan Z Wiktor (SZ)

Department of Global Health, University of Washington, Seattle, WA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH